Shares in Novo Nordisk, one of Europe’s largest listed companies, slumped on Monday after the company said that one of its diabetes drugs had failed to slow the progression of Alzheimer’s in late-stage trials.
Data from two large-scale clinical trials studying the effectiveness of treating early Alzheimer’s with semaglutide did not show any significant improvement in the thousands of patients enrolled in the study, the company said.
Novo said the trials, which enrolled nearly 4,000 patients, did not “translate into a delay of disease progression” even as it “resulted in improvement of Alzheimer’s disease-related biomarkers”.
您已閱讀15%（630字），剩余85%（3558字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。